论文部分内容阅读
目的 观察托吡酯在中国人群中的安全性和耐受性。方法 对1999年11月至2000年11月在协和医院癫(?)中心接受托吡酯单和添加治疗的150例癫(?)患者进行观察,总结分析不良反应发生的情况。结果 不良反应大多出现于开始治疗后2个月内,特别是在加量期,以体重减轻最常见,其他不良反应发生率低,并且绝大部分继续治疗后或适当调整药物剂量后消失。其中单药治疗组低于添加治疗组,差异有显著性。结论 在中国人群中,托吡酯安全性和耐受性好,值得推广应用。
Objective To observe the safety and tolerability of topiramate in Chinese population. Methods From November 1999 to November 2000 in the Union Hospital epilepsy center received topiramate and added 150 cases of epilepsy patients were observed and analyzed the incidence of adverse reactions. Results Most of the adverse reactions occurred within 2 months after the start of treatment, especially during the adjunct period. The most common cause was weight loss, and the incidence of other adverse reactions was low. Most of the adverse reactions disappeared after continued treatment or after proper dose adjustment. Among them, monotherapy group was lower than adding treatment group, the difference was significant. Conclusion Topiramate is safe and well tolerated in Chinese population, which is worthy of promotion and application.